SMARCA4, commonly mutated in various tumors, is associated with reduced sensitivity to traditional cancer treatments.736,737 Inhibiting SMARCA4/2 is an effective strategy for curbing tumor growth and improving patient outcomes. This evidence concerns the gene SMARCA4 and cancer.